Pathogen-specific recombinant human polyclonal antibodies: biodefence applications

Bibliography

• BURTON DR, SAPHIRE EO, PARREN PW: A model for neutralization of viruses based on antibody coating of the virion surface. Cuic Top. Microbial. Ioannina (2001) 260:109–143.
   PubMed Web of Science ®Google Scholar
• PARREN PW, BURTON DR: The antiviral activity of antibodies in vitro and in vivo. Adv. Immuna (2001) 77:195–262.
   PubMed Web of Science ®Google Scholar
• HENDERSON DA: The looming threat ofbioterrorism. Science (1999) 283:1279–1282.
   PubMed Web of Science ®Google Scholar
• •Brief introduction to the revival of American biodefence activities.
   Google Scholar
• LANE HC, LA MONTAGNE JR, FAUCI AS: Bioterrorism: a clear and present danger. Nat. Med. (2001) 7:1271–1273.
   PubMed Web of Science ®Google Scholar
• FAUCI AS: Biodefence on the research agenda. Nature (2003) 421:787–787.
   PubMed Web of Science ®Google Scholar
• PALMORE T, FOLKERS G, HEILMAN C, LA MONTAGNE JR, FAUCI AS: The NIAID research agenda on Biodefense. ASM News (2002) 68:375–382.
   Google Scholar
• CASADEVALL A: Antibodies for defense against biological attack. Nat. Biotechnol (2002) 20:114.
   PubMed Web of Science ®Google Scholar
• CASADEVALL A: Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Emerg. Infect. Dis. (2002) 8:833–841.
   PubMed Web of Science ®Google Scholar
• ••A thorough review of antibody administration against biological weapons, discussing mAb and pAb passive immunotherapy against CDC antigens.
   Google Scholar
• HUMPHREYS DP, GLOVER DJ: Therapeutic antibody production technologies: molecules, applications, expression and purification. Curt: Opin. Drug arc. Dev. (2001) 4:172–185.
   PubMedGoogle Scholar
• FARRUGIA A, POULIS P: Intravenous immunoglobulin: regulatory perspectives on use and supply. Tansfus. Med. (2001) 11:63–74.
   PubMed Web of Science ®Google Scholar
• LOOFBOUROW JC, CABASSO VJ, ROBY RE, ANUSKIEWICZ W: Rabies immune globulin (human). Clinical trials and dose determination. JAMA (1971) 217:1825–1831.
   Google Scholar
• BEASLEY RP, HWANG LY, STEVENS CEet al.: Efficacy of hepatitis B immune globulin for prevention of perinatal transmission of the hepatitis B virus carrier state: final report of a randomized double-blind, placebo-controlled trial. Hepatology (1983) 3:135–141.
   Google Scholar
• SNYDMAN DR: Historical overview of the use of cytomegalovirus hyperimmune globulin in organ transplantation. Transpl. Infect. Dis. (2001) 3\(Suppl. 2):6–13.
   Google Scholar
• KELLERMANN SA, GREEN LL: Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics. Cuic Opin. Biotechnol (2002) 13:593–597.
   PubMed Web of Science ®Google Scholar
• BREKKE OH, SANDLIE I: Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev Drug Discov. (2003) 2:52–62.
   PubMed Web of Science ®Google Scholar
• POLLACK P, GROOTHUIS JR: Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV. J. Infect. Chemothic (2002) 8:201–206.
   PubMedGoogle Scholar
• ROMERO JR: Palivizumab prophylaxis ofrespiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Pediatr. Infect. Dis. (2003) 22:S46–S54.
   Google Scholar
• SHARON J, SOMPURAM SR, YANG CY, WILLIAMS BR, SARANTOPOULOS S: Construction of polyclonal antibody libraries using phage display. Methods Ma Biol. (2002) 178:101–112.
   PubMedGoogle Scholar
• SHARON J, SARANTOPOULOS S, DEN W et al.: Recombinant polyclonal antibody libraries. Comb. Chem. High Throughput Screen. (2000) 3:185–196.
   PubMedGoogle Scholar
• EMEA, CPMP: Note for guidance on plasma-derived medicinal products. (2001):1–31.
   Google Scholar
• FDA, CBER: Points to consider in the manufacture and testing of monoclonal antibody products for human use. (1997):1–50.
   Google Scholar
• DIRECTIVE 75/318/EEC: Production and quality control of monoclonal antibodies. (1995):237–262.
   Google Scholar
• LANE JM, GOLDSTEIN J: Evaluation of 21st-Century risk of smallpox vaccination and policy options. Ann. Intern. Med. (2003) 138:488–493.
   PubMed Web of Science ®Google Scholar
• NO AUTHORS LISTED: Recommendations of the advisory committee on immunization practices (ACIP): rabies prevention - United States 1999. MMWR Morb. Mortal. Wkly Rep. (1999) 48(RR-1):1–21.
   Google Scholar
• BINDER P, ATTRE O, BOUTIN JP et al: Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Comp. Immuna Microbial. Infect. Dis. (2003) 26:401–421.
   PubMed Web of Science ®Google Scholar
• CIUREA A, HUNZIKER L, ZINKERNAGEL PM, HENGARTNER H: Viral escape from the neutralizing antibody response: the lymphocytic choriomeningitis virus model. Immunogenetics (2001) 53:185–189.
   PubMed Web of Science ®Google Scholar
• •Review of mechanisms of viral immune escape from neutralising antibody responses.
   Google Scholar
• GARCIA-BARRENO B, PORTELA A, DELGADO T, LOPEZ JA, MELERO JA: Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus. EMBO J. (1990) 9:4181–4187.
   PubMed Web of Science ®Google Scholar
• WEI X, DECKER JM, WANG S et al: Antibody neutralization and escape by HIV-1. Nature (2003) 422:307–312.
   PubMed Web of Science ®Google Scholar
• CASADEVALL A: Antibody-mediate immunity against intracellular pathogens: two dimensional thinking comes full circle. Infect. Inman. (2003) 71:4225–4228.
   PubMed Web of Science ®Google Scholar
• •Important discussion of the different outcomes of pathogen-specific responses against bacteria.
   Google Scholar
• PROFT T, FRASER JD: Bacterial superantigens. Clin. Exp. Immuna (2003) 133:299–306.
   PubMed Web of Science ®Google Scholar
• NOWAKOWSKI A, WANG C, POWERS DB et al: Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA (2002) 99:11346–11350.
   PubMed Web of Science ®Google Scholar
• ••Compelling demonstration of thesynergistic effect of oligoclonal cocktails of mAb directed against botulinurrt toxin compared with mAb.
   Google Scholar
• DARLING RG, CATLETT CL, HUEBNER KD, JARRET DG: Threats in bioterrorism. I: CDC category A agents. Emerg. Med. Clin. North Am. (2002) 20:273–309.
   PubMed Web of Science ®Google Scholar
• INGLESBY TV, HENDERSON DA, BARTLETT JG et al: Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (1999) 281:1735–1745.
   PubMed Web of Science ®Google Scholar
• LITTLE SF, IVINS BE, FELLOWS PF, FRIEDLANDER AM: Passive protection by polyclonal antibodies against Bacillus anthracisinfection in guinea pigs. Infect. Inman. (1997) 65:5171–5175.
   PubMed Web of Science ®Google Scholar
• ••Evidence from animal experiments thatpAbs are more efficient than mAbs in protecting against anthrax.
   Google Scholar
• CIRINO NM, SBLATTERO D, ALLEN D et al.: Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect. Inman. (1999) 67:2957–2963.
   PubMed Web of Science ®Google Scholar
• KOBILER D, GOZES Y, ROSENBERG H et al: Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Inman. (2002) 70:544–560.
   PubMed Web of Science ®Google Scholar
• ••Evidence from animal experiments thatpAbs are more efficient than mAbs in protecting against anthrax.
   Google Scholar
• MAYNARD JA, MAASSEN CB, LEPPLA SH et al: Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol (2002) 20:597–601.
   PubMed Web of Science ®Google Scholar
• REUVENY S, WHITE MD, ADAR YY et al.: Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Inman. (2001) 69:2888–2893.
   PubMed Web of Science ®Google Scholar
• WILD MA, XIN H, MARUYAMA T et al: Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol (2003) 21:1305–1306.
   PubMed Web of Science ®Google Scholar
• WELKOS S, LITTLE S, FRIEDLANDER A, FRITZ D, FELLOWS P: The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology (2001) 147:1677–1685.
   PubMedGoogle Scholar
• ARNON SS, SCHECHTER R, INGLESBY TV et al: Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 285:1059–1070.
   PubMed Web of Science ®Google Scholar
• TACKET CO, SHANDERA WX, MANN JM, HARGRETT NT, BLAKE PA: Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am. J. Med. (1984) 76:794–798.
   PubMed Web of Science ®Google Scholar
• HIBBS RG, WEBER JT, CORWIN A et al.: Experience with the use of an investigational F(ab')2 heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin. Infect. Dis. (1996) 23:337–340.
   PubMed Web of Science ®Google Scholar
• GELZLEICHTER TR, MYERS MA, MENTON RG et al.: Protection against botulinum toxins provided by passive immunization with botulinum human immune globulin: evaluation using an inhalation model.' Appl. Toxicol (1999) 19\(Suppl. 1):S35–S38.
   Google Scholar
• AMERSDORFER P, WONG C, CHEN S et al.: Molecular characterization of murine humoral immune response to botulinum neurotoxin type A binding domain as assessed by using phage antibody libraries. Infect. Inman. (1997) 65:3743–3752.
   PubMed Web of Science ®Google Scholar
• •Initial data revealing synergy from a cocktail of two mAbs directed against botulinum A toxin.
   Google Scholar
• PLESS DD, TORRES ER, REINKE EK, BAVARI S: High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A. Infect. Inman. (2001) 69:570–574.
   PubMed Web of Science ®Google Scholar
• BROWN DR, LLOYD JP, SCHMIDT JJ: Identification and characterization of a neutralizing monoclonal antibody against botulinum neurotoxin serotype F, following vaccination with active toxin. Hybridorna (1997) 16:447–456.
   PubMed Web of Science ®Google Scholar
• UNSINGERJ, KROGER A, HAUSER H, WIRTH D: Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes. Ma Tiler: (2001) 4:484–489.
   Google Scholar
• PERRY RD, FETHERSTON JD: Yersinia pestis-etiologic agent of plague. Clin. Microbiol Rev (1997) 10:35–66.
   PubMed Web of Science ®Google Scholar
• INGLESBY TV, DENNIS DT, HENDERSON DA et al.: Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA (2000) 283:2281–2290.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON ED, VESEY PM, GILLHESPY KJ et al: An IgG1 titre to the Fl and V antigens correlates with protection against plague in the mouse model. Clin. Exp. brununol. (1999) 116:107–114.
   PubMed Web of Science ®Google Scholar
• GROSFELD H, COHEN S, BINO T et al.: Effective protective immunity to Yersinia pestis infection conferred by DNA vaccine coding for derivatives of the Fl capsular antigen. Infect. Inman. (2003) 71:374–383.
   PubMed Web of Science ®Google Scholar
• GREEN M, ROGERS D, RUSSELL P et al.: The SCID/Beige mouse as a model to investigate protection against Yersinia pestis. FEMS Innnunol. Med. Microbiol (1999) 23:107–113.
   PubMed Web of Science ®Google Scholar
• HILL J, LEARY SE, GRIFFIN KF, WILLIAMSON ED, TITBALL RW: Regions of Yersinia pestisV antigen that contribute to protection against plague identified by passive and active immunization. Infect. Inman. (1997) 65:4476–4482.
   PubMed Web of Science ®Google Scholar
• HILL J, COPSE C, LEARY Set al.: Synergistic protection of mice against plague with monoclonal antibodies specific for the Fl and V antigens of Yersinia pest/v. Infect. Inman. (2003) 71:2234–2238.
   Google Scholar
• •Demonstrates synergistic activity of mAbs against Yersinia pestis
   Google Scholar
• WEEKS S, HILL J, FRIEDLANDER A, WELKOS S: Anti-V antigen antibody protects macrophages from Yersinia pestis - induced cell death and promotes phagocytosis. Microb. Pathog. (2002) 32:227–237.
   PubMed Web of Science ®Google Scholar
• ROGGENKAMP A, GEIGER AM, LEITRITZ L, KESSLER A, HEESEMANN J: Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen. Infect. Inman. (1997) 65:446–451.
   Google Scholar
• •An illustration of the impact of strain-specificity on the efficacy of passive irmnunotherapy against Yersinia.
   Google Scholar
• HENDERSON DA, INGLESBY TV, BARTLETT JG et al.: Smallpox as a biological weapon. JAMA (1999) 281:2127–2137.
   PubMed Web of Science ®Google Scholar
• BRAY M: Pathogenesis of potential antiviraltherapy for complications of small pox vaccination. Antiviral Res. (2003) 58:101–114.
   PubMed Web of Science ®Google Scholar
• GALMICHE MC, GOENAGA J, WITTEK R, RINDISBACHER L: Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology (1999) 254:71–80.
   PubMed Web of Science ®Google Scholar
• TIKUNOVA NV, BELANOV EF, MOROZOVA VV et al.: Phage antibodies neutralize vaccinia virus. Dokl. Biocirem. Biophys. (2002) 382:10–12.
   PubMedGoogle Scholar
• RAMIREZ JC, TAPIA E, ESTEBAN M: Administration to mice of a monoclonal antibody that neutralizes the intracellular mature virus form of vaccinia virus limits virus replication efficiently under prophylactic and therapeutic conditions. J. Gen. Viral. (2002) 83:1059–1067.
   PubMed Web of Science ®Google Scholar
• ISAACS SN, ARGYROPOULOS E, SFYROERA G, MOHAMMAD S, LAMBRIS JD: Restoration of complement-enhanced neutralization of vaccinia virus virions by novel monoclonal antibodies raised against the vaccinia virus complement control protein. " Vim] (2003) 77:8256–8262.
   Google Scholar
• DENNIS DT, INGLESBY TV, HENDERSON DA et al: Tularemia as a biological weapon: medical and public health management. JAMA (2001) 285:2763–2773.
   PubMed Web of Science ®Google Scholar
• DRABICK JJ, NARAYANAN RB, WILLIAMS JC, LEDUC JW, NACY CA: Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine. Ana. J. Med. Sci (1994) 308:83–87.
   PubMed Web of Science ®Google Scholar
• RHINEHART-JONES TR, FORTIER AH, ELKINS KL: Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect. Inman. (1994) 62:3129–3137.
   PubMed Web of Science ®Google Scholar
• FULOP M, MASTROENI P, GREEN M, TITBALL RW: Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis. Vaccine (2001) 19:4465–4472.
   PubMed Web of Science ®Google Scholar
• BORIO L, INGLESBY T, PETERS CJ et al.: Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA (2002) 287:2391–2405.
   PubMed Web of Science ®Google Scholar
• •Excellent review of potential biodefence implications of haemorrhagic viruses.
   Google Scholar
• KSIAZEK TG, ROLLIN PE, WILLIAMS AJ et al.: Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J. Infect. Dis. (1999) 179\(Suppl. 1):5177–5187.
   Google Scholar
• KORAKA P, MURGUE B, DEPARIS X et al.: Elevated levels of total and dengue virus-specific immunoglobulin E in patients with varying disease severity. J. Med. Vim] (2003) 70:91–98.
   PubMed Web of Science ®Google Scholar
• LEROY EM, BAIZE S, VOLCHKOV VE et al: Human asymptomatic Ebola infection and strong inflammatory response. Lancet (2000) 355:2210–2215.
   PubMed Web of Science ®Google Scholar
• LEROY EM, BAIZE S, DEBRE P, LANSOUD-SOUKATE J, MAVOUNGOU E: Early immune responses accompanying human asymptomatic Ebola infections. Clin. Exp. Inonunol. (2001) 124:453–460.
   PubMed Web of Science ®Google Scholar
• BECKER S, FELDMANN H, WILL C, SLENCZKA W: Evidence for occurrence of filovirus antibodies in humans and imported monkeys: do subclinical filovirus infections occur worldwide? Med. Microbiol brununol. (Berl) (1992) 181:43–55.
   PubMed Web of Science ®Google Scholar
• GONZALEZ JP, NAKOUNE E, SLENCZKA W, VIDAL P, MORVAN JM: Ebola and Marburg virus antibody prevalence in selected populations of the Central African Republic. Microbes Infect. (2000) 2:39–44.
   PubMed Web of Science ®Google Scholar
• GUNTHER S, KUHLE O, REHDER D et al.: Antibodies to Lassa virus Z protein and nucleoprotein co-occur in human sera from Lassa fever endemic regions. Med. Microbiol Irronunol (Berl) (2001) 189:225–229.
   PubMed Web of Science ®Google Scholar
• RIVAS YJ, MOROS Z, MORON D et al.: The seroprevalences of anti-hantavirus IgG antibodies among selected Venezuelan populations. Ann. Trop. Med. Parasitol (2003) 97:61–67.
   PubMed Web of Science ®Google Scholar
• MUPAPA K, MASSAMBA M, KIBADI K et al.: Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee." Infect. Dis. (1999) 179\(Suppl. 1):518–523.
   Google Scholar
• •Passive immunotherapy in eight cases of Ebola virus infection during the Congo 1995 epidemic, with a successful outcome in seven out of eight.
   Google Scholar
• CLAYTON AJ: Lassa immune serum. Bull. World Health Organ. (1977) 55:435–439.
   PubMed Web of Science ®Google Scholar
• JAHRLING PB, PETERS CJ, STEPHEN EL: Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J. Infect. Dis. (1984) 149:420–427.
   PubMed Web of Science ®Google Scholar
• MAIZTEGUI JI, FERNANDEZ NJ, DE DAMILANO AJ: Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet (1979) 2:1216–1217.
   PubMed Web of Science ®Google Scholar
• ENRIA DA, BRIGGILER AM, FERNANDEZ NJ, LEVIS SC, MAIZTEGUI JI: Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet (1984) 2:255–256.
   PubMed Web of Science ®Google Scholar
• JAHRLING PB, GEISBERT J, SWEARENGEN JR et al.: Passive immunization of Ebola virus-infected cynomolgus monkeys with immunoglobulin from hyperimmune horses. Arch. Vim] Sapp] (1996) 11:135–140.
   PubMedGoogle Scholar
• GUPTA M, MAHANTY S, BRAY M, AHMED R, ROLLIN PE: Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. " Vim/. (2001) 75:4649–4654.
   PubMed Web of Science ®Google Scholar
• KUDOYAROVA-ZUBAVICHENE NM, SERGEYEV NN, CHEPURNOV AA, NETESOV SV: Preparation and use of hyperimmune serum for prophylaxis and therapy of Ebola virus infections.' Infect. Dis. (1999) 179\(Suppl. 1):5218–5223.
   Google Scholar
• MARUYAMA T, RODRIGUEZ LL, JAHRLING PB et al.: Ebola virus can be effectively neutralized by antibody produced in natural human infection. J. Vim/. (1999) 73:6024–6030.
   Web of Science ®Google Scholar
• PARREN PW, GEISBERT IW, MARUYAMA T, JAHRLING PB, BURTON DR: Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. I. Vim/. (2002) 76:6408–6412.
   Google Scholar
• WILSON JA, HEVEY M, BAKKEN R et al.: Epitopes involved in antibody-mediated protection from Ebola virus. Science (2000) 287:1664–1666.
   PubMed Web of Science ®Google Scholar
• TAKADA A, WATANABE S, OKAZAKI K, KIDA H, KAWAOKA Y: Infectivity-enhancing antibodies to Ebola virus glycoprotein. Vim] (2001) 75:2324–2330.
   Google Scholar
• •Important study pointing towards the potential role of infectivity-enhancing antibodies in Ebola virus infection.
   Google Scholar
• TAKADA A, FELDMANN H, KSIAZEK TG, KAWAOKA Y: Antibody-dependent enhancement of Ebola virus infection. " Vim] (2003) 77:7539–7544.
   Google Scholar
• GEISBERT IW, HENSLEY LE, GEISBERT JB, JAHRLING PB: Evidence against an important role for infectivity-enhancing antibodies in Ebola virus infections. Virology (2002) 293:15–19.
   PubMed Web of Science ®Google Scholar
• JAHRLING PB, PETERS CJ: Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect. Inman. (1984) 44:528–533.
   PubMed Web of Science ®Google Scholar
• XU Z, WEI L, WANG L, WANG H, JIANG S: The in vitroand in vivoprotective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization. Biochem. Biophys. Res. Commun. (2002) 298:552–558.
   PubMed Web of Science ®Google Scholar
• KOCH J, LIANG M, QUEITSCH I, KRAUS AA, BAUTZ EK: Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology (2003) 308:64–73.
   PubMedGoogle Scholar
• MORAN GJ: Threats in bioterrorism. II: CDC category B and C agents. Emerg. Med. Clin. North Am. (2002) 20:311–330.
   Web of Science ®Google Scholar
• ROEHRIG JT, HUNT AR, KINNEY PM, MATHEWS JH: ha vitro mechanisms of monoclonal antibody neutralization of alphaviruses. Virology(1988) 165:66–73.
   PubMed Web of Science ®Google Scholar
• PHILLPOTTS RJ, JONES LD, HOWARD SC: Monoclonal antibody protects mice against infection and disease when given either before or up to 24 hours after airborne challenge with virulent Venezuelan equine encephalitis virus. Vaccine (2002) 20:1497–1504.
   PubMed Web of Science ®Google Scholar
• BEN NATHAN D, LUSTIG S, TAM G et al.: Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating west nile virus infection in mice. J. Infect. Dis. (2003) 188:5–12.
   PubMed Web of Science ®Google Scholar
• DIAMOND MS, SHRESTHA B, MARRI A, MAHAN D, ENGLE M: B cells and antibody play critical roles in the immediate defense of disseminated infection by west nile encephalitis virus. Virol (2003) 77:2578–2586.
   Web of Science ®Google Scholar
• CLOECKAERT A, JACQUES I, DE WERGIFOSSE P, DUBRAY G, LIMET JN: Protection against Brucella melitensis or Brucella abortus in mice with immunoglobulin G (IgG), IgA, and IgM monoclonal antibodies specific for a common epitope shared by the Brucella A and M smooth lipopolysaccharides. Infect. Inman. (1992) 60:312–315.
   PubMed Web of Science ®Google Scholar
• ELZER PH, JACOBSON RH, JONES SM et al.: Antibody-mediated protection against Brucella abortus in BALB/c mice at successive periods after infection: variation between virulent strain 2308 and attenuated vaccine strain 19. Immunology (1994) 82:651–658.
   PubMed Web of Science ®Google Scholar
• BINDER P, ATTRE O, BOUTIN JP et al: Medical management of biological warfare and bioterrorism: place of the immunoprevention and the immunotherapy. Comp. Immunol Microbiol Infect. Dis. (2003) 26:401–421.
   PubMed Web of Science ®Google Scholar
• KNUDSEN TB, KLEDAL TN, ANDERSEN O, EUGEN-OLSEN J, KRISTIANSEN TB: Severe acute respiratory syndrome - a new coronavirus from the Chinese Dragon's Lair. Scand. Immunol (2003) 58:277–284.
   PubMed Web of Science ®Google Scholar
• STEPHENSON J: Monkeypox outbreak a reminder of emerging infections vulnerabilities. JA/VIA (2003) 290:23–24.
   Web of Science ®Google Scholar
• HATTA M, KAWAOKA Y: The continued pandemic threat posed by avian influenza virus in Hong Kong. Trends Microbiol (2002) 10:340–344.
   PubMed Web of Science ®Google Scholar
• ZHOU B, WIRSCHING P, JANDA KD: Human antibodies against spores of the genus Bacilluc a model study for detection of and protection against anthrax and the bioterrorist threat. Proc. Natl. Acad. Sci. USA (2002) 99:5241–5246.
   PubMed Web of Science ®Google Scholar
• SARANTOPOULOS S, KAO CY, DEN W, SHARON J: A method for linking VL and VH region genes that allows bulk transfer between vectors for use in generating polyclonal IgG libraries. Immunol (1994) 152:5344–5351.
   Web of Science ®Google Scholar
• FREY SE, NEWMAN FK, CRUZ J et al.: Dose-related effects of smallpox vaccine. N Engl. J. Med. (2002) 346:1275–1280.
   PubMed Web of Science ®Google Scholar
• KOCH J, LIANG M, QUEITSCH I, KRAUS AA, BAUTZ EK: Human recombinant neutralizing antibodies against hantaan virus G2 protein. Virology (2003) 308:64–73.
   PubMedGoogle Scholar
• MARUYAMA T, PARREN PWHI, SANCHEZ A et al: Recombinant human monoclonal antibodies to Ebola virus. J. Infect. Dis. (1999) 179\(Suppl. 1):5235–5239.
   Google Scholar